ATE275948T1 - Verwendung von adamantan derivaten zur herstellung eines medikaments zur glaukombehandlung - Google Patents

Verwendung von adamantan derivaten zur herstellung eines medikaments zur glaukombehandlung

Info

Publication number
ATE275948T1
ATE275948T1 AT94903488T AT94903488T ATE275948T1 AT E275948 T1 ATE275948 T1 AT E275948T1 AT 94903488 T AT94903488 T AT 94903488T AT 94903488 T AT94903488 T AT 94903488T AT E275948 T1 ATE275948 T1 AT E275948T1
Authority
AT
Austria
Prior art keywords
medication
producing
glaucoma treatment
adamantan
derivatives
Prior art date
Application number
AT94903488T
Other languages
English (en)
Inventor
Stuart A Lipton
Evan B Dreyer
Original Assignee
Massachusetts Eye & Ear Infirm
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirm, Childrens Medical Center filed Critical Massachusetts Eye & Ear Infirm
Application granted granted Critical
Publication of ATE275948T1 publication Critical patent/ATE275948T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94903488T 1992-12-04 1993-12-06 Verwendung von adamantan derivaten zur herstellung eines medikaments zur glaukombehandlung ATE275948T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/984,939 US5922773A (en) 1992-12-04 1992-12-04 Glaucoma treatment
PCT/US1993/011833 WO1994013275A1 (en) 1992-12-04 1993-12-06 Glaucoma treatment

Publications (1)

Publication Number Publication Date
ATE275948T1 true ATE275948T1 (de) 2004-10-15

Family

ID=25531050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94903488T ATE275948T1 (de) 1992-12-04 1993-12-06 Verwendung von adamantan derivaten zur herstellung eines medikaments zur glaukombehandlung

Country Status (11)

Country Link
US (1) US5922773A (de)
EP (1) EP0671910B1 (de)
JP (2) JPH08506807A (de)
KR (1) KR960700046A (de)
AT (1) ATE275948T1 (de)
AU (1) AU683634B2 (de)
CA (1) CA2150933C (de)
DE (1) DE69333626T2 (de)
ES (1) ES2229213T3 (de)
PT (1) PT671910E (de)
WO (1) WO1994013275A1 (de)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
AU716577B2 (en) * 1994-07-06 2000-03-02 Sanofi-Aventis Use of polyamine antagonists for the treatment of glaucoma
JPH08231400A (ja) * 1995-02-24 1996-09-10 Rohto Pharmaceut Co Ltd イフェンプロジルを必須成分とする眼圧降下剤
JPH0967270A (ja) * 1995-08-31 1997-03-11 Res Dev Corp Of Japan 水晶体混濁の予防および治療法、並びにそのための薬 剤
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
CA2237898A1 (en) * 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US5965534A (en) * 1995-11-22 1999-10-12 Alcon Laboratories, Inc. Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
JP3719609B2 (ja) 1995-12-21 2005-11-24 アルコン ラボラトリーズ，インコーポレイテッド 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
CA2241913A1 (en) * 1996-01-02 1997-07-10 Synthelabo Use of polyamine site antagonist for the manufacture of a medicament for the treatment of ischemic disorders of the eye
WO1997033582A1 (fr) * 1996-03-14 1997-09-18 Synthelabo Compositions d'antagonistes de site polyamine
US5891871A (en) * 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
CA2252962A1 (en) * 1996-04-26 1997-11-06 Fujisawa Pharmaceutical Co., Ltd. Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
ES2317650T3 (es) * 1996-10-28 2009-04-16 Senju Pharmaceutical Co., Ltd. Farmacos para mejorar trastornos circulatorios oculares.
CA2275167C (en) 1996-12-16 2008-10-28 Alcon Laboratories, Inc. The topical use of kappa opioid agonists to treat ocular pain
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
WO1999008521A1 (en) * 1997-08-14 1999-02-25 Department Of The Army, U.S. Government Treatment or prophylaxis of retinal pathology and spinal cord injury
AU1388999A (en) * 1997-12-16 1999-07-05 Alcon Laboratories, Inc. The use of nitric oxide generations for the treatment of dry eye disorders
JP2002503692A (ja) * 1998-02-23 2002-02-05 藤沢薬品工業株式会社 マクロライド系化合物の緑内障治療用途
EP1066039A4 (de) 1998-03-02 2003-02-26 Cocensys Inc Substituierte quinazoline und deren analoge und verwendungen
AU5251999A (en) * 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
WO2000038703A1 (en) * 1998-12-24 2000-07-06 R-Tech Ueno, Ltd. Agent for treating visual cell function disorder
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
CA2368242A1 (en) * 1999-03-12 2000-09-21 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
WO2001010442A1 (en) * 1999-08-09 2001-02-15 Fujisawa Pharmaceutical Co., Ltd. Retinal ganglion cell death inhibitors containing dihydropyridine compounds
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
CA2386579A1 (en) * 1999-11-12 2001-05-25 Alcon, Inc. Neurophilin ligands for treating ocular conditions
US6462066B2 (en) 1999-12-02 2002-10-08 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
EP1252895A4 (de) * 2000-01-31 2003-04-16 Santen Pharmaceutical Co Ltd Heilmittel für ophthalmologische zustände
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
CN100460874C (zh) * 2000-02-29 2009-02-11 阿尔康公司 筛检卷曲相关蛋白激动剂或拮抗剂的方法
US6927233B1 (en) 2000-03-17 2005-08-09 Alcon, Inc. 5ht2 agonists for controlling IOP and treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
WO2001070705A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
CN1444587A (zh) * 2000-05-30 2003-09-24 奥索-麦克尼尔药品公司 二氢吡啶软药及相关组合物和方法
CA2416169C (en) 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
EP1346728A1 (de) * 2000-11-22 2003-09-24 Mitsubishi Pharma Corporation Ophthalmologische zubereitungen
FR2822706A1 (fr) * 2001-03-29 2002-10-04 Univ Pasteur Utilisation de composes organiques antagonistes de recepteurs pour le traitement de la degenerescence retinienne
US6583152B2 (en) * 2001-04-30 2003-06-24 Dexgen Pharmaceuticals, Inc. Composition for reducing the risk or progression of cardiovascular diseases
AU2002259312B2 (en) 2001-06-01 2007-01-04 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
CA2447156A1 (en) 2001-06-01 2002-12-12 Alcon, Inc. Novel fused indazoles and indoles and their use for the treatment of glaucoma
ATE318821T1 (de) 2001-06-01 2006-03-15 Alcon Inc Pyranoindazole und ihre verwendung in der glaukombehandlung
EP1513589B1 (de) 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
US8557855B2 (en) 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
EP1581503A4 (de) 2002-11-08 2007-07-25 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
BR0316775A (pt) 2002-12-13 2005-11-01 Alcon Inc Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
AU2003297363A1 (en) * 2002-12-23 2004-07-22 Alcon, Inc. Use of cathepsin k inhibitors for the treatment of glaucoma
WO2004069275A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation 眼科用剤
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
ZA200508166B (en) 2003-04-17 2007-03-28 Toyama Chemical Co Ltd Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
EP1654002B2 (de) * 2003-08-07 2014-01-29 Allergan, Inc. Zusammensetzungen zur abgabe von therapeutika in die augen
AU2004268012B2 (en) 2003-09-02 2008-11-20 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
BRPI0414102A (pt) 2003-09-04 2006-10-31 Merck & Co Inc composto, uso do mesmo, e, composição
US7494983B2 (en) 2003-09-04 2009-02-24 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
EP1706095B1 (de) 2004-01-20 2008-12-24 Allergan, Inc. Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
US7563816B2 (en) 2004-07-20 2009-07-21 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20080033053A1 (en) * 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
JP2008507588A (ja) * 2004-07-26 2008-03-13 アラーガン、インコーポレイテッド 眼の病態を処置する方法
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
US20080009546A1 (en) * 2005-05-06 2008-01-10 Chevron U.S.A. Inc. Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
EP1885689A1 (de) * 2005-05-06 2008-02-13 Chevron U.S.A., Inc. Diamondoidderivate mit therapeutischer wirkung
WO2007002781A2 (en) * 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
US20090197930A1 (en) * 2006-02-02 2009-08-06 Kenji Yoshida Eyedrops
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
EA017648B1 (ru) * 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
BRPI0816970A2 (pt) * 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
CA2704436C (en) * 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
JP2010235597A (ja) * 2009-03-10 2010-10-21 Santen Pharmaceut Co Ltd ４，６−ジクロロ−１ｈ−インドール−２−カルボン酸誘導体又はその塩を有効成分として含有する視神経障害の予防又は治療剤
WO2010112615A1 (en) 2009-04-03 2010-10-07 Dsm Ip Assets B.V. Lysine derivatives functionalised with lipids
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
NZ598668A (en) 2009-09-01 2014-07-25 Lz Therapeutics Inc Methods for extraction and purification of gangliosides
WO2011028797A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of glaucoma and other retinopathies with gangliosides
NZ716349A (en) 2009-11-09 2017-07-28 Allergan Inc Compositions and methods for stimulating hair growth
EP2555750A2 (de) 2010-04-07 2013-02-13 Allergan, Inc. Kombinationen aus konservierungsstoffzusammensetzungen für ophthalmische formulierungen
KR20130041803A (ko) 2010-04-07 2013-04-25 알러간, 인코포레이티드 안과 조성물을 위한 보존제의 조합
JP5562716B2 (ja) * 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
EP2661435B1 (de) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
EP2602654B1 (de) * 2011-12-08 2023-04-19 Essilor International Ophthalmischer Filter
MX2014008797A (es) 2012-01-20 2014-10-30 Garnet Biotherapeutics Inc Metodos para la produccion gangliosidos.
EP2956096A1 (de) 2013-02-15 2015-12-23 Allergan, Inc. Implantat mit langzeit-wirkstofffreisetzung
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
EP3223793B1 (de) 2014-11-25 2023-06-28 Eximore Ltd. Zusammensetzungen und verfahren zur abgabe eines bioaktiven wirkstoffs oder bioaktiver wirkstoffe
US11234897B2 (en) 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966749A (en) * 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
US4396625A (en) * 1980-05-13 1983-08-02 Sumitomo Chemical Company, Limited Treatment of glaucoma or ocular hypertension and ophthalmic composition
US4425346A (en) * 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
WO1988005306A1 (en) * 1987-01-23 1988-07-28 The General Hospital Corporation Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction)
US4981871A (en) * 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
US5070088A (en) * 1989-12-19 1991-12-03 E. R. Squibb & Sons, Inc. Pyranyl quinoline calcium channel blockers
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
CA2131101A1 (en) * 1992-05-13 1993-11-25 Louis Desantis Jr. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
US5435998A (en) * 1994-08-03 1995-07-25 Abelson; Mark B. Treatment of low-tension glaucoma by topical administration of calcium channel blocking agents

Also Published As

Publication number Publication date
JPH08506807A (ja) 1996-07-23
KR960700046A (ko) 1996-01-19
US5922773A (en) 1999-07-13
JP2006070039A (ja) 2006-03-16
EP0671910A1 (de) 1995-09-20
DE69333626D1 (de) 2004-10-21
WO1994013275A1 (en) 1994-06-23
EP0671910A4 (de) 1999-01-13
ES2229213T3 (es) 2005-04-16
PT671910E (pt) 2004-12-31
DE69333626T2 (de) 2005-02-10
EP0671910B1 (de) 2004-09-15
CA2150933A1 (en) 1994-06-23
AU683634B2 (en) 1997-11-20
CA2150933C (en) 2010-02-09
AU5741494A (en) 1994-07-04

Similar Documents

Publication Publication Date Title
DE69333626D1 (de) Verwendung von Adamantan Derivaten zur Herstellung eines Medikaments zur GLAUKOMBEHANDLUNG
DE3687099D1 (de) Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.
ATE324884T1 (de) Verwendung von gamma-linolensäure oder dihomogammalinolensäure zur herstellung eines medikaments zur behandlung von huntington's chorea
ATE205389T1 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
ATE133336T1 (de) Verwendung von rapamycin zur herstellung eines arzneimittels zur behandlung von augenentzündungen
GEP20002146B (en) Therapeutic Peptide Derivatives
DE69836352D1 (de) Transdermales therapeutisches Pflaster mit Capsaicin und seinen Analogen
NO952469D0 (no) Terapautisk kombinasjon som inneholder interferon
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE230605T1 (de) Wundheilmittel und behandlung von fibrotischen storungen durch tgfbeta-3
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
DE69400631D1 (de) Verwendung von rifamycinderivaten zur herstellung eines arzneimittels zur behandlung der toxoplasmose
DE69826023D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
ATE63815T1 (de) Verwendung von zinn-protoporphyrin und zinnmesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.
DE69825887D1 (de) Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE70441T1 (de) Vitaminhaltiges mittel zur behandlung und zum schutz der schleimhaeute sowie verwendung von vitamin e zur herstellung des mittels.
MY130107A (en) Piperidylmethyl-substituted chroman derivatives
ATE23112T1 (de) Verwendung von 1-(p-isopropoxyethoxymethylphenoxy)-3-isopropylamino-propan-2-ol zur herstellung eines arzneimittels zur senkung des augeninnendrucks.
KR950702433A (ko) Tcf-ii를 유효성분으로 하는 혈장 응고 정상화제

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0671910

Country of ref document: EP